SBP GROUP (01177) shares rose nearly 3%, up 2.32% as of press time to HK$5.29, with turnover of HK$47.9849 million.
On the news front, on October 14, SBP GROUP issued an announcement that a clinical study result of TQ-A3334 (a TLR7 agonist), a National Class 1 innovative drug independently developed by the group's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) for the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented in an oral presentation; Bepirovirsen (ASO), a product under strategic collaboration between Chia Tai Tianqing and GSK, has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
- Like
- Comment
- Favorite
SBP GROUP Shares Climb Nearly 3% as Latest TQ-A3334 and Bepirovirsen Research Findings Set to Be Unveiled at 2026 AASLD
Stock News10-15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet